EL7.AI
StocksMedium•19 November 2026•
4 min read

VivoSim Announces Seven-Figure Agreement, Sees Revenue Growth Exceeding 500% in 2027

Key Facts

1VivoSim announced a seven-figure agreement on November 19 with a pharmaceutical company ranked among the world’s top 10.
2VivoSim expects to exceed its previous revenue growth guidance of more than 500% for fiscal 2027.
3The company reported revenue of 51 thousand dollars in the quarter ended September 30, 2026, including 22 thousand dollars in service revenue.
4Cash was about 8.6 million dollars, and operating cash flow was an outflow of about 5.7 million dollars during the six months through September 30, 2026.

VivoSim announced on November 19, 2026, that it had signed an agreement described as seven-figure with a global pharmaceutical company ranked among the sector’s top 10, and said it expects to exceed its previous guidance for revenue growth of more than 500% in fiscal 2027. The customer’s name and the agreement’s exact value were not disclosed in the published summary of the announcement. The deal puts toxicity testing services at the center of the company’s expansion plans, with NAMkind tests expected to be included in the customer’s recurring preclinical work. The summary also reported growth in liver and gut toxicity testing in the quarter ended September 30, 2026. The 2027 growth outlook remains company guidance, and no published details were available on the agreement’s exact value or revenue schedule.

The reference to growth in testing follows results for the quarter ended September 30, when VivoSim posted total revenue of 51 thousand dollars, compared with 28 thousand dollars in the same period of 2025. Service revenue was 22 thousand dollars, the company’s first quarterly service revenue. The remaining 29 thousand dollars came from royalties, showing that the services business tied to the new agreement was at an early stage when the results were announced. The company said in its quarterly report that its primary focus in the coming period is growing service revenue. It added that it expects this activity to increase in coming quarters, a path that depends on converting tests into recurring customer work.

On July 15, 2026, the company had forecast revenue growth of more than 500% in fiscal 2027, citing customer response to the predictive power of its models and a broader customer base. On the same date, it said it had received a 5 million dollar milestone payment from Eli Lilly after the first patient began Phase 2 of the drug program sold to the company. It also said it was eligible to receive up to 45 million dollars in additional milestone payments across development, regulatory and commercial stages, subject to meeting specified milestones. Those payments are separate from the testing agreement announced in November and do not, on their own, disclose the value of revenue that may result from the new agreement. The earlier growth guidance is based on the company’s expectations, while the new agreement announcement adds commercial activity that the company said could support that trajectory.

The September 30 data show the company’s financing position: cash and cash equivalents totaled about 8.6 million dollars. Operating cash flow was an outflow of about 5.7 million dollars during the six months ended on that date. The company said in its report that these conditions raise substantial doubt about its ability to continue as a going concern for at least one year, and that it needs additional funding. This means potential service growth comes as the company monitors its cash needs, while the published information does not estimate the new agreement’s contribution to liquidity or the timing of its revenue collection. In August, VivoSim said it had regained compliance with Nasdaq’s minimum stockholders’ equity requirement of 2.5 million dollars, following a notice on August 4.

The stock closed at 0.12 dollars on November 18, according to EL7 daily data, on the eve of the agreement announcement. Historical price data for investors showed closes of 0.12 dollars on November 16, 17 and 18, with trading volume of 258439 shares on November 18, compared with 231880 shares on November 16. These data alone do not establish a price response to the announcement issued on November 19. One risk still facing the company is regaining compliance with Nasdaq’s minimum bid price requirement of one dollar per share. Nasdaq had granted it an initial 180-day period, ending February 16, 2027, to regain compliance.

Open on chart